Business Context and Reporting Period
Company: Ventrus Biosciences, Inc. (Note: Input metadata referenced "Assembly Biosciences," but the filing text identifies the registrant as Ventrus Biosciences, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Ventrus is a development-stage specialty pharmaceutical company focused on late-stage prescription drugs for gastrointestinal disorders: hemorrhoids (VEN 309), anal fissures (VEN 307), and fecal incontinence (VEN 308). The company has no approved products and generates no product revenue. It completed its Initial Public Offering (IPO) on December 22, 2010.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(15,290,625) | $(4,539,405) |
| Accumulated Deficit (Inception to 12/31/10) | $(33,184,354) | $(17,893,729) |
| Cash and Cash Equivalents (12/31/10) | $14,571,055 | $81,288 |
| Total Assets (12/31/10) | $14,616,601 | $166,254 |
| Total Liabilities (12/31/10) | $2,990,485 | $13,528,902 |
| Net Cash Used in Operating Activities | $(5,214,427) | $(3,483,919) |
| Net Cash Provided by Financing Activities | $19,704,194 | $3,551,929 |
Debt and Liquidity: As of December 31, 2010, the company held approximately $14.6 million in cash, primarily from the IPO. Outstanding debt included $1,573,000 in principal under promissory notes to Paramount Credit Partners (due 2013 or upon a qualifying transaction) and $1,219,380 in short-term borrowings (repaid in January 2011 via IPO over-allotment proceeds).
Material Changes vs. Prior Period
- Capitalization: The company transitioned from a private entity with minimal cash ($81k) to a public company with significant liquidity ($14.6M) following the December 2010 IPO, which raised net proceeds of approximately $15.2 million.
- Debt Conversion: Significant debt obligations ($14 million in principal and accrued interest) from 2007 and 2010 convertible notes were automatically converted into common stock upon the IPO closing, reducing total liabilities from $13.5 million in 2009 to $3.0 million in 2010.
- Operating Expenses:
- Research & Development (R&D): Decreased 37% to $1.85 million in 2010 from $2.94 million in 2009, primarily due to the absence of a $1.6 million contractual payment expensed in 2009.
- General & Administrative (G&A): Increased 634% to $2.92 million in 2010 from $0.4 million in 2009, driven largely by $2.3 million in stock-based compensation for options granted to employees and directors.
- Interest Expense: Increased 84% to $10.5 million in 2010, largely due to a $6.0 million non-cash charge for the beneficial conversion feature (BCF) associated with debt conversions and amortization of debt discounts.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Cash Runway: Management believes existing cash is sufficient to fund operations into the third quarter of 2012.
- Development Timeline:
- VEN 309 (Hemorrhoids): Phase III trial initiation expected mid-2011; data availability Q1 2012. NDA submission anticipated mid-2014; approval earliest 2015.
- VEN 307 (Anal Fissures): Partner S.L.A. Pharma conducting Phase III in Europe (data expected Q2 2012). U.S. pivotal trials to follow contingent on capital and formulation decisions. NDA submission anticipated 2013.
- VEN 308 (Fecal Incontinence): Development paused in short term; Phase IIb study planned for 2012 if capital is raised.
- Capital Needs: Estimated future costs to complete development are $20 million for VEN 309, $15 million for VEN 307, and $20 million for VEN 308. Additional financing will be required.
Risks and Contingencies:
- Material Weaknesses: The company identified material weaknesses in internal controls over financial reporting (lack of accounting expertise, segregation of duties, and independent review). Remediation steps include hiring a permanent CFO and upgrading software.
- Licensing Obligations: Failure to meet substantial milestone and royalty payments to licensors (S.L.A. Pharma and Sam Amer & Co.) could result in license termination. Total potential milestone payments exceed $40 million across products.
- Patent Uncertainty: The patent for VEN 307 (diltiazem) is pending appeal; if not issued, the company may only have 3 years of market exclusivity post-approval.
- Related Party Transactions: Significant debt and equity relationships exist with affiliates of Dr. Lindsay Rosenwald, the largest stockholder.
Key Facts for Investor Verification
- Revenue Status: Verify that the company has zero product revenue and relies entirely on financing for operations.
- Debt Conversion Terms: Confirm the conversion price of $4.20 per share (70% of IPO price) for the $14 million in convertible notes converted in December 2010.
- Licensing Milestones: Review the specific triggers for the $800,000 payment to S.L.A. Pharma (completion of European Phase III enrollment) and the $20 million potential milestone caps.
- Internal Controls: Monitor the remediation of identified material weaknesses in financial reporting, as failure could impact future reporting reliability.
- Patent Status: Track the status of the U.S. Patent Application No. 09/355,928 for VEN 307, which is critical for long-term exclusivity.